Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer
Authors:
Open Access
- 13 April 2015
- journal article
- research article
- Published by Impact Journals, LLC in Oncotarget
- Vol. 6 (11) , 9073-9085
Abstract
Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancer Dual inhibition of HDAC and EGFR signaling with CUDC-101 induces potent suppression of tumor growth and metastasis in anaplastic thyroid cancerKeywords
This publication has 50 references indexed in Scilit:
- Cell Cycle Deregulation andTP53andRASMutations Are Major Events in Poorly Differentiated and Undifferentiated Thyroid CarcinomasThe Journal of Clinical Endocrinology & Metabolism, 2014
- New and emerging HDAC inhibitors for cancer treatmentJournal of Clinical Investigation, 2014
- The role of chemotherapy and latest emerging target therapies in anaplastic thyroid cancerOncoTargets and Therapy, 2013
- Phase II Trial of Sorafenib in Patients with Advanced Anaplastic Carcinoma of the ThyroidThyroid®, 2013
- BRAF V600E Inhibition in Anaplastic Thyroid CancerNew England Journal of Medicine, 2013
- Four clinically utilized drugs were identified and validated for treatment of adrenocortical cancer using quantitative high-throughput screeningJournal of Translational Medicine, 2012
- Targeted Inhibition of Src Kinase with Dasatinib Blocks Thyroid Cancer Growth and MetastasisClinical Cancer Research, 2012
- Late Intervention with anti-BRAFV600E Therapy Induces Tumor Regression in an Orthotopic Mouse Model of Human Anaplastic Thyroid CancerEndocrinology, 2012
- Induction Chemotherapy with Weekly Paclitaxel Administration for Anaplastic Thyroid CarcinomaThyroid®, 2010
- Gene p53 mutations are restricted to poorly differentiated and undifferentiated carcinomas of the thyroid gland.Journal of Clinical Investigation, 1993